Track topics on Twitter Track topics that are important to you
VPGMarketResearchrsquo;s new report is a study of the major business opportunities emerging in the European cancer diagnostics market during the next five years. The report examines trends in major European countries; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
France, Germany, Italy, Spain, UK
European Market Overview
Fiveyear test volume and sales projections by country.
Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
Estimated universe of laboratories performing cancer diagnostic testing by country.
Cancer statistics, etiology and recent developments.
Business Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially significant market appeal during the next five years.
Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Test
Colony Stimulating Factors
Immunohistochemical Stains, and others.
ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
Sales and market shares of major cancer diagnostic product suppliers by individual test and country.
Fiveyear test volume and sales forecasts for major tumor markers by country and market segment, including:
Physician Offices/Group Practices
Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Strategic assessments ofnbsp;major suppliers and startup firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in Ramp;D.
Companies analyzed in the report include:
nbsp;nbsp; Agilent Technologies
nbsp;nbsp; Applied Gene Technologies
nbsp;nbsp; Arca Biopharma
nbsp;nbsp; Beckman Coulter/Danaher
nbsp;nbsp; Becton Dickinson
nbsp;nbsp; Biomedical Diagnostics
nbsp;nbsp; Correlogic Systems/Vermillion
nbsp;nbsp; Decode Genetics
nbsp;nbsp; Eiken Chemical
nbsp;nbsp; Elitech Group
nbsp;nbsp; Enzo Biochem
nbsp;nbsp; Exact Sciences
nbsp;nbsp; Guided Therapeutics
nbsp;nbsp; Kyowa Medex
nbsp;nbsp; Mackay Life Sciences
nbsp;nbsp; Myriad Genetics
nbsp;nbsp; OrthoClinical Diagnostics
nbsp;nbsp; Panacea Pharmaceuticals
nbsp;nbsp; Quest Diagnostics
nbsp;nbsp; Radient Pharmaceuticals
nbsp;nbsp; Siemens Healthcare
nbsp;nbsp; Takara Bio
nbsp;nbsp; Targeted Diagnostics amp; Therapeutics
nbsp;nbsp; Thermo Fisher
nbsp;nbsp; Wako Pure Chemicals
Contains 820 pages and 320 tables
Original Article: Europe Cancer Diagnostics Market Analysis 2021: France, Germany, Italy, Spain, UKSupplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation [Updated: 01011970] Prices from USD $19700NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...